{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:50:45Z","timestamp":1793742645405,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejradiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Radiology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejrad.2025.112499","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T01:35:50Z","timestamp":1761788150000},"page":"112499","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Chest computed tomography of trastuzumab-deruxtecan (T-DXd)-related interstitial lung disease: Key points for radiologists"],"prefix":"10.1016","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4480-8872","authenticated-orcid":false,"given":"L.","family":"Cereser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Della Rossa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Sparascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gerratana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.M.","family":"Minisini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Puglisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Girometti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Zuiani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejrad.2025.112499_b0005","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: the \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ejrad.2025.112499_b0010","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"DESTINY-breast01 investigators, trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2025.112499_b0015","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"DESTINY-Gastric01 investigators, trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2025.112499_b0020","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejrad.2025.112499_b0025","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"DESTINY-CRC01 investigators, Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejrad.2025.112499_b0030","doi-asserted-by":"crossref","first-page":"4125","DOI":"10.1007\/s12325-024-02975-x","article-title":"Efficacy of trastuzumab deruxtecan in HER2-expressing solid tumors by enrollment HER2 IHC status: post hoc analysis of DESTINY-pantumor02","volume":"41","author":"Oaknin","year":"2024","journal-title":"Adv. Ther."},{"key":"10.1016\/j.ejrad.2025.112499_b0035","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/s13244-024-01771-z","article-title":"The radiologist's role in detecting systemic anticancer therapy-related interstitial lung disease: an educational review","volume":"15","author":"Dinkel","year":"2024","journal-title":"Insights Imaging."},{"key":"10.1016\/j.ejrad.2025.112499_b0040","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.clbc.2023.09.005","article-title":"Efficacy and safety of trastuzumab deruxtecan in breast cancer: a systematic review and meta-analysis","volume":"23","author":"Dowling","year":"2023","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.ejrad.2025.112499_b0045","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-022-01736-w","article-title":"Trastuzumab deruxtecan-induced interstitial lung disease\/pneumonitis in ERBB2-positive advanced solid malignancies: a systematic review","volume":"82","author":"Abuhelwa","year":"2022","journal-title":"Drugs"},{"key":"10.1016\/j.ejrad.2025.112499_b0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: a systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejrad.2025.112499_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejrad.2025.112499_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis-Focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.ejrad.2025.112499_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1565872","article-title":"From tissue-specific to tissue-agnostic: HER2 overexpression and the rise of antibody-drug conjugates","volume":"15","author":"Ko","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejrad.2025.112499_b0070","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1158\/1078-0432.CCR-18-2275","article-title":"Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer","volume":"25","author":"Meric-Bernstam","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejrad.2025.112499_b0075","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"DESTINY-Lung01 trial investigators, trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2025.112499_b0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"DESTINY-Breast04 trial investigators, trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2025.112499_b0085","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"DESTINY-Breast03 trial investigators, trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Cort\u00e9s","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejrad.2025.112499_b0090","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1001\/jamaoncol.2021.3595","article-title":"Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review","volume":"7","author":"Tarantino","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejrad.2025.112499_b0095","doi-asserted-by":"crossref","first-page":"8019","DOI":"10.3390\/curroncol30090582","article-title":"Managing the risk of lung toxicity with trastuzumab deruxtecan (T-DXd): a Canadian perspective","volume":"30","author":"Henning","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejrad.2025.112499_b0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejrad.2025.112499_b0105","first-page":"953","article-title":"Expression of the HER-2\/neu proto-oncogene in normal human adult and fetal tissues","volume":"5","author":"Press","year":"1990","journal-title":"Oncogene"},{"key":"10.1016\/j.ejrad.2025.112499_b0110","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1080\/14740338.2023.2204228","article-title":"High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive\/mutated malignancies: a pharmacovigilance study based on the FAERS database","volume":"22","author":"Ma","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.ejrad.2025.112499_b0115","unstructured":"National Cancer Institute, CTCAE and Adverse Event Reporting, CTCAE v5.0 quick reference 2017, Available at: https:\/\/dctd.cancer.gov\/research\/ctep-trials\/for-sites\/adverse-events#ctep-ctcae."},{"key":"10.1016\/j.ejrad.2025.112499_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejrad.2025.112499_b0125","unstructured":"US Food and Drug Administration, Center for Drug Evaluation and Research, NDA\/BLA multidisciplinary review and evaluation {BLA 761139} ENHERTU (famtrastuzumab deruxtecan-nxki) 2019, Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/761139Orig1s000MultidisciplineR.pdf."},{"key":"10.1016\/j.ejrad.2025.112499_b0130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.2174\/1874306401206010063","article-title":"Drug induced interstitial lung disease","volume":"6","author":"Schwaiblmair","year":"2012","journal-title":"Open Respir. Med. J."},{"key":"10.1016\/j.ejrad.2025.112499_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100404","article-title":"Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment","volume":"7","author":"Conte","year":"2022","journal-title":"ESMO Open"},{"key":"10.1016\/j.ejrad.2025.112499_b0140","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.2147\/DDDT.S508773","article-title":"A systematic review of mechanisms, incidence, and management of trastuzumab deruxtecan induced ILD\/pneumonitis in solid tumors","volume":"19","author":"Liao","year":"2025","journal-title":"Drug Des Devel Ther."},{"key":"10.1016\/j.ejrad.2025.112499_b0145","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1164\/ajrccm.165.2.ats01","article-title":"American Thoracic Society\/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias","volume":"165","author":"American Thoracic Society; European Respiratory Society","year":"2002","journal-title":"Am J Respir Crit Care Med."},{"key":"10.1016\/j.ejrad.2025.112499_b0150","article-title":"Drug-related pneumonitis in the era of precision cancer therapy","volume":"1","author":"Nishino","year":"2017","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.ejrad.2025.112499_b0155","unstructured":"Introductory Guide for Standardised MedDRA Queries (SMQs) Version 25.0, 2022, https:\/\/admin.meddra.org\/sites\/default\/files\/guidance\/file\/SMQ_intguide_25_0_English.pdf."},{"key":"10.1016\/j.ejrad.2025.112499_b0160","article-title":"Trastuzumab deruxtecan\u2012related interstitial lung disease\/pneumonitis: computed tomography imaging patterns to guide diagnosis and management","volume":"7","author":"Nishino","year":"2023","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.ejrad.2025.112499_b0165","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4048\/jbc.2022.25.e1","article-title":"CT findings from interstitial lung diseases in patients with metastatic breast cancer treated with fam-trastuzumab deruxtecan: a single institutional experience","volume":"25","author":"Jang","year":"2022","journal-title":"J. Breast Cancer"},{"key":"10.1016\/j.ejrad.2025.112499_b0170","doi-asserted-by":"crossref","unstructured":"T. Baba, M. Kusumoto, T. Kato, Y. Kurihara, S. Sasaki, K. Oikado, Y. Saito, M. Endo, Y. Fujiwara, H. Kenmotsu, M. Sata, T. Takano, K. Kato, K. Hirata, T. Katagiri, H. Saito, K. Kuwano, Clinical and imaging features of interstitial lung disease in cancer patients treated with trastuzumab deruxtecan, Int J Clin Oncol. 28 (2023) 1585\u20131596. https:\/\/doi.org\/10.1007\/s10147-023-02414-x. Epub 2023 Oct 3. Erratum in: Int J Clin Oncol. 29 (2024) 78\u201379. https:\/\/doi.org\/10.1007\/s10147-023-02427-6.","DOI":"10.1007\/s10147-023-02414-x"},{"key":"10.1016\/j.ejrad.2025.112499_b0175","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.1016\/j.annonc.2024.08.294","article-title":"18346MO Trastuzumab deruxtecan (T-DXd) associated interstitial lung disease (ILD) in a large real-world French cohort of patients with HER2-driven breast cancer and other malignancies","volume":"35","author":"Canellas","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ejrad.2025.112499_b0180","doi-asserted-by":"crossref","unstructured":"K. Tamura, J. Tsurutani, S. Takahashi, H. Iwata, I.E. Krop, C. Redfern, Y. Sagara, T. Doi, H. Park, R.K. Murthy, R.A. Redman, T. Jikoh, C. Lee, M. Sugihara, J. Shahidi, A. Yver, S. Modi, Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study, Lancet Oncol. 20 (2019) 816\u2013826. https:\/\/doi.org\/10.1016\/S1470-2045(19)30097-X. Epub 2019 Apr 29. Erratum in: Lancet Oncol. 20 (2019) e293. https:\/\/doi.org\/10.1016\/S1470-2045(19)30292-X.","DOI":"10.1016\/S1470-2045(19)30097-X"},{"key":"10.1016\/j.ejrad.2025.112499_b0185","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0033-8389(05)70334-1","article-title":"CT signs and patterns of lung disease","volume":"39","author":"Collins","year":"2001","journal-title":"Radiol. Clin. North Am."},{"key":"10.1016\/j.ejrad.2025.112499_b0190","doi-asserted-by":"crossref","DOI":"10.1148\/radiol.232558","article-title":"Fleischner society: glossary of terms for thoracic imaging","volume":"310","author":"Bankier","year":"2024","journal-title":"Radiology"},{"key":"10.1016\/j.ejrad.2025.112499_b0195","doi-asserted-by":"crossref","first-page":"e0928","DOI":"10.1002\/rcr2.928","article-title":"Two cases of trastuzumab deruxtecan-induced interstitial lung disease in advanced breast cancer","volume":"10","author":"Gocho","year":"2022","journal-title":"Respirol Case Rep"},{"key":"10.1016\/j.ejrad.2025.112499_b0200","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02776-2021","article-title":"Drug-induced interstitial lung disease","volume":"60","author":"Spagnolo","year":"2022","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ejrad.2025.112499_b0205","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1148\/radiol.2021203427","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner society","volume":"298","author":"Johkoh","year":"2021","journal-title":"Radiology"},{"key":"10.1016\/j.ejrad.2025.112499_b0210","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.chest.2021.12.659","article-title":"Algorithmic approach to the diagnosis of organizing pneumonia: a correlation of clinical, radiologic, and pathologic features","volume":"162","author":"Cherian","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.ejrad.2025.112499_b0215","first-page":"80","article-title":"Drug-induced lung disease: a brief update for radiologists","volume":"29","author":"Ufuk","year":"2023","journal-title":"Diagn. Interv. Radiol."},{"issue":"Suppl 5","key":"10.1016\/j.ejrad.2025.112499_b0220","first-page":"v1","volume":"63","author":"Bradley","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.ejrad.2025.112499_b0225","doi-asserted-by":"crossref","DOI":"10.1148\/rg.220176","article-title":"CT approach to lung injury","volume":"43","author":"Marquis","year":"2023","journal-title":"Radiographics"},{"key":"10.1016\/j.ejrad.2025.112499_b0230","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1164\/rccm.2204013","article-title":"Acute interstitial pneumonia: clues from the white stuff","volume":"165","author":"Hansell","year":"2002","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejrad.2025.112499_b0235","doi-asserted-by":"crossref","DOI":"10.1164\/rccm.202005-2032ST","article-title":"Diagnosis of Hypersensitivity Pneumonitis in adults. An official ATS\/JRS\/ALAT clinical practice guideline","volume":"202","author":"Raghu","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejrad.2025.112499_b0240","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2024.104274","article-title":"Lung toxicity induced by anti-HER2 antibody-drug conjugates for breast cancer","volume":"195","author":"Chai","year":"2024","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ejrad.2025.112499_b0245","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.3390\/cancers14122937","article-title":"Sarcoid-like granulomatosis associated with immune checkpoint inhibitors in melanoma","volume":"14","author":"Melin","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejrad.2025.112499_b0250","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1148\/rg.220073","article-title":"Interstitial lung abnormalities at CT: subtypes, clinical significance, and associations with lung cancer","volume":"42","author":"Hata","year":"2022","journal-title":"Radiographics"},{"key":"10.1016\/j.ejrad.2025.112499_b0255","doi-asserted-by":"crossref","first-page":"3717","DOI":"10.1038\/s41591-024-03261-7","article-title":"DESTINY-Breast12 Study Group, Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b\/4 trial","volume":"30","author":"Harbeck","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejrad.2025.112499_b0260","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-253647","article-title":"Pneumocystis jirovecii pneumonia in a patient treated with trastuzumab-deruxtecan","volume":"16","author":"Mallah","year":"2023","journal-title":"BMJ Case Rep."},{"key":"10.1016\/j.ejrad.2025.112499_b0265","article-title":"Concurrent trastuzumab deruxtecan-induced interstitial lung disease and COVID-19 in the treatment of advanced breast cancer","volume":"12","author":"Yasuda","year":"2023","journal-title":"Oxf. Med. Case Reports"}],"container-title":["European Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25005856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0720048X25005856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T19:36:46Z","timestamp":1768333006000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0720048X25005856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":53,"alternative-id":["S0720048X25005856"],"URL":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112499","relation":{},"ISSN":["0720-048X"],"issn-type":[{"value":"0720-048X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chest computed tomography of trastuzumab-deruxtecan (T-DXd)-related interstitial lung disease: Key points for radiologists","name":"articletitle","label":"Article Title"},{"value":"European Journal of Radiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejrad.2025.112499","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"112499"}}